Clinical and molecular features in a cohort of Middle Eastern patients with epidermolysis bullosa
Pediatric Dermatology · 2023
DOI: 10.1111/pde.15440 ↗At a glance
Journal article in Pediatric Dermatology, 2023. Written by Shir Bergson and 17 co-authors. Institution: Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Major MEDLINE topics: Epidermolysis Bullosa, Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Simplex. Cited 2 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Israel Science Foundation, Ministry of Science and Technology, Israel.
Abstract (original language)
Background
Epidermolysis bullosa (EB) features skin and mucosal fragility due to pathogenic variants in genes encoding components of the cutaneous basement membrane. Based on the level of separation within the dermal‐epidermal junction, EB is sub‐classified into four major types including EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler EB (KEB) with 16 EB‐associated genes reported to date.
Methods
We ascertained a cohort of 151 EB patients of various Middle Eastern ethnic backgrounds.
Results
The cohort was comprised of EBS (64%, 97/151), DEB (21%, 31/151), JEB (12%, 18/151), and KEB (3%, 5/151). KRT14 and KRT5 variants were most common among EBS patients with 43% (42/97) and 46% (45/97) of EBS patients carrying mutations in either of these two genes, respectively. Truncal involvement was more common in KRT14 ‐associated EBS as compared to EBS due to KRT5 mutations ( p < .05). Mutations in COL17A1 and laminin 332‐encoding genes were identified in 55% (10/18) and 45% (8/18) of JEB patients. Scarring alopecia, caries, and EB nevi were most common among JEB patients carrying COL17A1 mutations as compared to laminin 332‐associated JEB ( p < .05). Abnormal nails were evident in most DEB and JEB patients while poikiloderma was exclusively observed in KEB ( p < .001).
Conclusions
EB patients of Middle Eastern origin were found to feature specific phenotype–genotype correlations of relevance to the diagnosis and genetic counseling of patients in this region.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Institute of Human Genetics, Galilee Medical Center, Nahariya, Israel.
- The Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
- Department of Dermatology, Rambam Health Care Campus, Haifa, Israel.
- Bruce and Ruth Rappaport Faculty of Medicine, Haifa, Israel.
ORCID profiles: Jacob Mashiah, Eli Sprecher, Liat Samuelov
Funding
- Israel Science Foundation
- Ministry of Science and Technology, Israel
Cite
APA
Bergson, S., Daniely, D., Bomze, D., Mohamad, J., Malovitski, K., Meijers, O., Briskin, V., Bihari, O., Malchin, N., Israeli, S., Mashiah, J., Falik-Zaccai, T., Avitan-Hersh, E., Eskin-Schwartz, M., Allon-Shalev, S., Sarig, O., Sprecher, E., & Samuelov, L. (2023). Clinical and molecular features in a cohort of Middle Eastern patients with epidermolysis bullosa. Pediatric Dermatology. https://doi.org/10.1111/pde.15440
Vancouver
Bergson S, Daniely D, Bomze D, Mohamad J, Malovitski K, Meijers O, et al. Clinical and molecular features in a cohort of Middle Eastern patients with epidermolysis bullosa. Pediatric Dermatology. 2023. doi:10.1111/pde.15440
BibTeX
@article{Bergson2023,
author = {Bergson, Shir and Daniely, Daniel and Bomze, David and Mohamad, Janan and Malovitski, Kiril and Meijers, Odile and Briskin, Valeria and Bihari, Ofer and Malchin, Natalia and Israeli, Shirli and Mashiah, Jacob and Falik-Zaccai, Tzipora and Avitan-Hersh, Emily and Eskin-Schwartz, Marina and Allon-Shalev, Stavit and Sarig, Ofer and Sprecher, Eli and Samuelov, Liat},
title = {Clinical and molecular features in a cohort of Middle Eastern patients with epidermolysis bullosa},
journal = {Pediatric Dermatology},
year = {2023},
doi = {10.1111/pde.15440}
}
EUVIMED